Literature DB >> 10401031

Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria?

P Glynne1, A Deacon, D Goldsmith, C Pusey, E Clutterbuck.   

Abstract

Bullous dermatoses (BD) are well recognized in patients with end-stage renal disease (ESRD). It is important to distinguish pseudoporphyria (porphyrin accumulation due to decreased clearance) from true porphyrias, particularly those in which acute neurological attacks may occur. Investigation of the dialysis patient poses practical diagnostic difficulties because urinary porphyrin profiles are not available. We describe a patient on continuous ambulatory peritoneal dialysis (CAPD) with several recognized causative factors for porphyria cutanea tarda (PCT). The patient presented with a blistering photosensitive rash. We highlight the importance of investigating anuric patients with fractionation of both fecal and plasma porphyrins. Plasma porphyrins were grossly elevated (345 nmol/L; reference range, <13), whereas plasma porphyrins in a control group of CAPD patients without blistering rashes were only minimally elevated (mean, 23.9 nmol/L; SD, 11.0; n = 9). Fractionation of fecal porphyrins by high-performance liquid chromatography (HPLC) yielded a pattern typical of PCT. In addition to the contributory factors for PCT that were present, it is possible that porphyrin accumulation secondary to renal failure played a role in the expression of her disease. Patients with ESRD presenting with BD require careful evaluation, including fractionation of fecal porphyrins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401031     DOI: 10.1016/s0272-6386(99)70123-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

Review 1.  ACP Best Practice No 165: front line tests for the investigation of suspected porphyria.

Authors:  A C Deacon; G H Elder
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

2.  Pseudoporphyria in a peritoneal dialysis patient.

Authors:  Arzu Velioglu; Tulin Ergun; Cetin Ozener
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

3.  [High-dose vitamin therapy as prophylaxis against porphyria cutanea uremica].

Authors:  F Wimmershoff; K Gardlo; K Bolsen; T Ruzicka; C Fritsch
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

Review 4.  Skin problems in chronic kidney disease.

Authors:  Dirk R J Kuypers
Journal:  Nat Clin Pract Nephrol       Date:  2009-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.